Drugs / Antiscorpion venom serum
Antiscorpion venom serum
also known as
Anti-scorpion venom serum Alacramyn · Anti-scorpion venom serum Birmex · AScVS · serum antiscorpion
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT01415830 | Aug 2011 → May 2012 | scorpion envenomation | Birmex | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT00739440 | Aug → Oct 2008 | scorpion envenomation | Birmex | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00753064 Comparator | Sep 2006 → Dec 2007 | scorpion envenomation | Haffkine Bio-Pharmaceutical Corporation Ltd. | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Antiscorpion venom serum | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00753064 ↗ |
| Known as | Anti-scorpion venom serum Alacramyn | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01415830 ↗ |
| Known as | Anti-scorpion venom serum Birmex | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01415830 ↗ |
| Known as | AScVS | “Antiscorpion venom serum(AScVS).” NCT00753064 ↗ |
| Known as | serum antiscorpion | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00739440 ↗ |
| Modality | Protein / enzyme biologic | “enzyme refined AScVS ( Monovalent Anti-scorpion venom serum against Mesobuthus tamulus concanesis Pocock.)” NCT00753064 ↗ |
| Route | Intravenous | “Computed doses were given according to clinical grading as intravenous bolus slowly.” NCT00753064 ↗ |